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Abstract. Endotoxemia in dogs was induced by a slow intravenous infusion o f E. coli 
endotoxin for 2 h. Thereby, a significant decrease was observed in the plasma levels o f 
several clotting, fibrinolysis and complement factors. The changes were studied over an 
experimental period o f 14 h and checked for statistical significance by three-way analysis o f 
variance. Applicat ion o f the broad-spectrum proteinase inhibi tor aprotinin (Trasylol®) 
from bovine organs clearly lowered the endotoxin-induced decline o f the plasma proteins 
studied. By intravenous application o f a specific granulocytic proteinase inhibi tor (Bow-
man-Birk inhibi tor from soybeans), the endotoxin-induced reduction o f the plasma pro-
teins was prevented in a similar manner. It can be concluded that at least some o f the 
pathobiochemical mechanisms observed in clotting, fibrinolysis and complement systems 
during endotoxemia are not only caused by a severe consumption reaction but also by 
unspecific proteolytic degradation due to neutral granulocytic proteinases. 
Introduction 
Characteristic changes in the clotting, fibrinolysis and complement sys-
tems (summarized as 'blood systems') during both gram-negative sepsis in 
man or experimental endotoxin shock in other mammalian species are 
usually considered to be an indication of disseminated intravascular coagu-
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lation (DIC) [1, 15, 16, 18, 19, 26, 28]. There are, however, divergent views 
concerning the trigger mechanism of endotoxin-induced DIC [26, 28, 29]. 
Direct activation of the coagulation system by endotoxin does not play any 
major role since the amounts of endotoxin, highly active in vivo, only cause 
minor changes in the coagulation system in vitro [28]. More likely, the 
release of several activators from leukocytes [20, 22, 24, 25, 30, 35], plate-
lets [29, 30] and endothelial cells [11, 26, 34] leads to specific activation of 
the above-mentioned blood systems resulting in severe consumption (DIC) 
of the involved proteins. Besides this drastic activation followed by elimi-
nation of the plasma proteins via complex formation with inhibitors (in the 
case of the blood system proteinases) or specific degradation (e.g. of factor V 
and VIII) , an unspecific proteolytic degradation of plasma proteins by gran-
ulocytic proteinases is also discussed [8-10, 38]. Only recently it has been 
demonstrated that both human and dog granulocytes contain large amounts 
of neutral proteinases such as elastase and cathepsin G , which are probably 
released by stimulation with endotoxin [2, 8, 10, 40]. The activities of clot-
ting factors either in their isolated form or in plasma are strongly reduced by 
digestion with elastase or cathepsin G [10, 39]. Even in vivo the reduction 
of such factors could be due to degradation by these proteinases under cer-
tain pathological conditions [9]. 
The in vitro interactions of human granulocytic elastase and cathepsin 
G with proteinase inhibitors from animal, plant and microbial tissues have 
been thoroughly investigated [37]. Interactions under in vivo conditions 
could also be demonstrated indirectly by application of an elastase-cathep-
sin G inhibitor (Bowman-Birk inhibitor, BBI) in the course of experimental 
gram-negative sepsis in dogs [38]. Inhibitor medication (BBI infusion) pre-
vented the rapid fall in activity of the fibrin-stabilizing factor, F XIII . The 
authors suggested that the decrease in F XIII activity is caused by direct 
nonspecific proteolysis rather than by the action of thrombin throughout 
severe DIC. 
The purpose of this investigation was: (i) to establish an endotoxemia 
model by studying the concentration patterns of several clotting (prothrom-
bin, antithrombin III , F XIII) , fibrinolysis (plasminogen, antiplasmin) and 
complement (C3) factors after slow intravenous endotoxin infusion in dogs; 
(ii) to study the therapeutical effect of a relatively specific inhibitor of gran-
ulocytic elastase and cathepsin G (BBI) on the concentration pattern of the 
above-mentioned proteins, and (iii) to distinguish between consumption of 
plasma proteins by D I C and/or by nonspecific proteolytic degradation due 
to granulocytic proteinases. To achieve this purpose we applied both BBI 
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directed against granulocytic proteinases and the broad spectrum proteinase 
inhibitor aprotinin, the effective agent in the drug Trasylol®. Aprotinin 
should be able to prevent primarily the activation of the clotting and fibri­
nolysis systems (and thus indirectly also the complement system) by inhibi­
tion of plasma kallikrein and of plasmin. 
Materials and Methods 
Endotoxin and Proteinase Inhibitors Used 
Endotoxin o f E. coli 026: Κ 60 (Β) Η 11 (Η 31 l b ) was prepared by extraction with 
trichloroacetic acid and heated phenol according to O'Neill and Todd [33]. 
The elastase-cathepsin G inhibi tor from soybeans (type: Bowman-Birk) was isolated 
from a raw extract ( 'trypsin inhibi tor from soybeans', Serva No. 37340) by gel filtration on 
Sephadex G-75 (Pharmacia, Uppsala) wi th 2 % acetic acid as eluant. The inhibitor-contain­
ing fractions were sampled, freeze-dried, and redissolved in an isotonic saline solution; the 
p H value was adjusted to 7.4 by 2 j V N a O H [43]. 
The trypsin-kallikrein inhibi tor aprotinin from bovine organs, trade name Trasylol® 
(6,660 kall ikrein inhibi tor units/mg), was obtained from Bayer A G , Wuppertal-Elber­
feld. 
Experimental Procedure 
Animals. 12 mongrel dogs o f either sex served to establish an endotoxemia model. 6 
animals were randomly allocated to the control (placebo) group and another 6 dogs to the 
endotoxemia group. 4 dogs were employed for the BBI medication group, 6 dogs for the 
aprotinin group only to observe trends o f the inhibi tor therapy. 
Experiments. Anesthesia was induced by intravenous application o f 30 mg/kg body 
weight o f pentobarbital (Nembuta l®) . Small doses o f this drug were given further on as 
bolus injections during the experimental period. For laryngeal catheterization we used a 
cuffed endotracheal tube. For catheterization o f the descending aorta a nylon catheter was 
inserted via the femoral artery. The inferior vena cava was catheterized via the femoral 
vein. Mean aortic blood pressure (PA) and heart rate were monitored continuously using a 
Siemens oscillograph recorder and a Statham element. 
Endotoxin Application. Endotoxemia was induced by continuous infusion o f 2 mg/kg 
body weight o f E. coli endotoxin, dissolved in isotonic saline solution, into the inferior 
vena cava over a 2-hour period. Control animals were subjected to the same experimental 
procedure except that they received a sterile isotonic saline solution (placebo) instead o f 
endotoxin solution. 
Sampling Procedure. The first data (mean aortic blood pressure, blood samples) were 
collected immediately after onset o f anesthesia and just before application o f endotoxin. 
Treatment wi th the endotoxin lasted 2 h. A t this t ime and 6, 10 and 14 h after starting the 
experiment additional data were recorded. Each t ime two 4.5-ml blood samples from the 
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inferior vena cava were withdrawn into plastic syringes containing 0.5 m l o f sodium citrate 
(2.2 %l 100 m l distilled water). I f the blood samples were not analyzed immediately after 
withdrawal, they were stored at - 7 0 ° C unti l assayed. Throughout the experiment all ani-
mals received a constant infusion o f an isotonic saline solution (40 ml /h) . The withdrawn 
blood volume d id not exceed 50 ml/dog over the experimental period o f 14 h. 
Inhibitor Application. In inhibitor-medicated dogs endotoxin and inhibi tor infusion 
were started simultaneously, but the inhibi tor application was continued over the 14-hour 
experimental period. Each o f these animals received per kilogram body weight, 10-25 
inhibi tor units (3-8 mg) o f BBI or 40,000 or 80,000 kallikrein inhibi tor units o f Trasy-
lol . 
Special Methods 
Blood Cells. Leukocyte counting was performed in a cell counter (Coulter Counter, 
M o d . B) while platelets were determined using a counting chamber (Neubauer Z ä h l k a m -
mer). Whole blood hemoglobin and hematocrit values were measured using a hemoglo-
binometer (Counter Electronics Ltd.) and microhematocrit capillaries. 
Amidolytic Activities of Clotting and Fibrinolysis Factors. The amidolytic activities o f 
individual factors were determined using specific chromogenic peptide substrates. Chro-
mozym T H (Tos-Gly-Pro-Arg-pNA) for prothrombin determination was from Boehringer, 
Mannheim; S-2238 (H-D-Phe-Pip-Arg-pNA) for ant i thrombin I I I determination and 
S-2251 (H-D-Val-Leu-Lys-pNA) for plasminogen and antiplasmin determination were do-
nated by Deutsche Kabi , Munich , and Kabi Diagnostica, Stockholm, Sweden. The com-
mercial companies' instructions were modified as indicated in table I . 
Biological Activity of Clotting Factor F XIII. The biological activity o f the f ibr in-
stabilizing factor ( F X I I I ) was measured wi th a marketable test system (Faktor X I I I -
Schnelltest, Behringwerke Marburg, No. 0TXS 10) according to the modification o f Bohn 
and Haupt [5]. By applying very small d i lu t ion steps, this semiquantitative test was refined 
to a nearly quantitative method. As the concentrations o f F X I I I varied significantly 
between individual animals, the activity changes throughout the experiment are given as 
percentages o f the individual starting value. 
Immunochemical Determination of Complement Factor C3. Complement factor C3 
was quantified by modifying the single radial immunodiffusion technique o f Mancini et al. 
[27] as follows: 3 ml o f 1 % agarose was mixed wi th 150 μΐ antiserum o f goat anti-dog C3 
(Nordic, Ti lburg, The Netherlands) and the mixture poured into transparent boxes from 
Desaga, Heidelberg. Precipitation was achieved in each case by applying 10μ1 o f 1:8 
diluted dog plasma into suitable wells. Internal standardization was done by setting up a 
di lu t ion series (1:8, 1:16, 1:32) o f each dog's starting plasma. The diameters o f the pre­
cipitat ion rings were squared and plotted against the concentration in percentages (100%, 
50%, 25%). From these graphs, the changes in the C3 amount in percent were determined 
for each animal throughout the experiment. 
Table I . Conditions for the photometric measurements o f various clotting and fibrinolysis factors wi th chromogenic substrates 
Buffer Dog 
plasma 
μΐ 
Act ivat ion Incubation Chromogenic 
substrate 
μΐ μΐ p H by μΐ m i n ° C 
Prothrombin 1,025 8.6 30 cephalin 1 100 125 
(0.05 Μ Tris, 
0.1 Λ / N a C l , 
0.01 M C a C l 2 , 
10 μg Trasylol/ml) 
(diluted 1:20 
wi th 0.9% NaCl) 
R V V 2 
(= 
50 
6 Mg) 
5 25 (chromozym T H , 
1.5 M) 
Ant i th rombin I I I 370 8.4 30 thrombin 100 300 
(0.05 Μ Tris, 
7.5 mM E D T A , 
3 I U heparin/ml) 
(diluted 1:100 
wi th buffer) 
(45 nkat/25 ml) 5 25 (S-2238, 0.75 M\ 
1 mg 
polybreneVml) 
Plasminogen 300 7.4 20 Kabikinase 40 840 
(0.05 Μ Tris, 
0.12 Μ NaCl) 
(diluted 1:5 
wi th buffer) 
(= streptokinase) 
(8,000 I U ) 
20 37 (S-2251, 3 xx\M) 
Antiplasmin 380 7.4 20 plasmin 400 200 
(0.05 Μ Tris, 
0.12 Μ NaCl) 
(undiluted) (22 nkat/10 m l 
buffer) 
1 25 (S-2251, 3.5 mM) 
I U = Inhibi tor units. 
1 PTT reagent from Boehringer, Mannheim. 
2 Russers viper venom from Sigma, Munich . 
3 From EGA-Chemie, Steinheim. 
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Stalistical Evaluations 
Three-Way Analysis of Variance. To study the established endotoxemia model, the 
statistical evaluation o f the differences between the control (placebo) group (n = 6) and the 
endotoxemia group (n = 6) was done by a three-way analysis o f variance without replica­
tions [7] . The random factor 'animals' was considered to be nested wi th in the treatment 
groups since the animals could only be observed under endotoxin or placebo, respectively. 
Treatment (endotoxin or placebo) and time were used in the analytical model as fixed 
factors. Therefore different effects could be analyzed: the effects o f treatment and t ime and 
the interaction between time and treatment. The existence o f a significant interaction 
between time and treatment was interpreted as different t ime courses in the placebo group 
and the endotoxemia group. The level o f significance was established at ρ < 0.05. For the 
different parameters the values obtained just before the application o f endotoxin or placebo 
served as 100% values. 
Student's t Test. Statistical evaluation o f the results obtained from endotoxemia ani­
mals wi th inhibitor-treatment (n = 4 for BBI and η = 6 for aprotinin) and the corresponding 
endotoxin-treated dogs (n = 6) was performed by Student's t test for independent observa­
tions. Considering that the tests were not independent we used the t tests only to observe 
trends o f the inhibi tor therapy. We considered ρ values < 0.05 to be appropriate for 
interpretation. 
Results 
Endotoxemia Model 
Aortic Blood Pressure. At the end of the endotoxin infusion period the 
mean aortic blood pressure was reduced from 18.11 ± 0.88 to 13.86 ± 
1.04 kPa (mean ± SEM). The blood pressure usually remained constant at 
this level until termination of the experiment. This difference turned out, 
however, to be not statistically significant (table II). 
Hematological Data. The blood hemoglobin and hematocrit values in 
the control group did not differ significantly (table II) from those of the 
endotoxemia group, although there was a moderate hemoconcentration in 
the animals of the latter group as described by other authors, too [1]. Endo­
toxin infusion caused a substantial and rapid decrease of circulating plate-
lets (starting value: χ = 251,700 ± 22,923 cells/μΐ; 2-hour value: χ = 98,233 
± 18,396 cells/μΐ). From the end of endotoxin infusion until the end of the 
experiment only a small increase in cell count (x = 145,060 ± 15,226 
cells/μΐ) was observed (fig. 1). Similarly, a marked decline occurred in the 
numbers of circulating leukocytes ranging from approximately 9,000 to 
4,000 cells/μΐ during the endotoxin-infusion period (fig. 2). From the 6th 
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ι 
U 
Fig. 1. Changes in the platelet counts during the acute phase o f experimental endo-
toxemia in dogs (mean values ± SEM). = Control group (n = 6); = endotoxin 
group (n = 6); thick line at the abscissa = endotoxin infusion period. 
Table I I . Three-way analysis o f variance in an endotoxemia model wi th dogs (control 
group η = 6, endotoxin group η = 6) 
Parameter ρ values for differences in 
groups time points time courses 
between groups 
Leukocytes 0.006 0.001 0.001 
Thrombocytes 0.001 0.001 0.001 
Factor X I I I 0.001 0.001 0.001 
Prothrombin 0.003 0.001 0.001 
An t i th rombin I I I 0.05 0.001 0.004 
Plasminogen 0.003 0.001 0.05 
Ant iplasmin 0.002 0.001 0.004 
Complement C3 0.001 0.001 0.003 
Aort ic blood pressure 0.22 (n.s.) 0.001 0.368 (n.s.) 
Hemoglobin 0.207 (n.s.) 0.960 (n.s.) 0.043 
Hematocrit 0.111 (n.s.) 0.123 (n.s.) 0.043 
The significances (p values) are indicated for the differences between the control and the 
endotoxin group as well as for different behavior o f both groups at each time point and 
during the whole t ime course o f experimental treatment, 
n.s. = Not significant. 
2 0 -
Platelets 
2 5 -
- — — τ" 
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Fig. 2. Changes in the leukocyte counts during the acute phase o f experimental endo­
toxemia in dogs (mean values ± SEM). = Control group (n = 6); = endotoxin 
group (n = 6); thick line at the abscissa = endotoxin infusion period. 
until the 14th h, however, a strong leukocytosis developed leading to leuko­
cyte counts (x = 20,000 ± 2,790 cells/μΐ) being far higher than before endo­
toxin application. 
Clotting Parameters. In the animals receiving endotoxin the plasma 
levels of prothrombin and antithrombin III (fig. 3) declined linearly up to 
the 6th h and remained nearly constant at these levels (14-hour value for 
prothrombin: χ = 34.2 ± 8.5%; for antithrombin III: χ = 62.8 ± 10 %. As 
indicated in table II, these values were reduced most significantly for pro­
thrombin but less so for antithrombin III. The biological activity of FXIII 
(fig. 3) was strongly affected by the endotoxin infusion decreasing linearly to 
χ = 39.2 ± 4.7% at the end of the observation period. 
Fibrinolysis Parameters. Plasminogen levels (fig. 3) fell markedly dur­
ing endotoxin infusion resulting after 14 h in a mean value of χ = 47.4 ± 
7.9%. The antiplasmin levels (fig. 3), determined as 'immediate' antiplas-
min activity (a2-antiplasmin, [41]), nearly paralleled the decrease in plas­
minogen concentration to χ = 48.6 ± 7.8% at the 14th h. 
Complement Factor C3. A significant drop in the plasma concentration 
of C3 to χ = 56.4 ± 9.6% of the starting value was already observed during 
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—ι 
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Fig. 3. Changes in the plasma levels o f various plasma factors during the acute phase 
o f experimental endotoxemia in dogs (standard deviations are indicated in table I I I ) . Thick 
line at the abscissa = endotoxin infusion period. · = Complement C3; * = factor X I I I ; Δ = 
prothrombin; • = ant i thrombin I I I ; • = plasminogen; • = antiplasmin. For further details 
see text. 
the endotoxin application period. At the end of the experiment (14th h) the 
concentration had finally reached χ = 30.8 ± 2.8% (fig. 3). In comparison, 
the control animals showed only a small decrease in their C3 level (x = 86.0 
± 4.9%) up to the 14th experimental hour. 
Inhibitor-Treated Animals 
Hematological Data. The blood hemoglobin and hematocrit values of 
the animals subjected to inhibitor therapy showed no significant changes 
compared to those of the endotoxemia dogs. 
As already demonstrated in figure 1, there was a dramatic decline of 
circulating platelets during the endotoxin infusion period, followed there-
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Fig. 4. Changes in the plasma levels o f various plasma factors during the acute phase 
o f inhibitor-treated experimental endotoxemia in dogs (standard deviations are indicated 
in table I I I ) . A Aprotinin-treated group (n = 6). Β Bowman-Birk inhibitor-treated group (n 
= 4). Thick line at the abscissa = endotoxin infusion period. For definition o f the symbols 
see figure 3. For further details see text. 
after by a modest increase in cell count. It seems that this endotoxin-
induced fluctuation could not be influenced by either BBI or aprotinin 
application. Similarly, dogs subjected to BBI or aprotinin treatment showed 
a fluctuation in leukocyte numbers comparable to that of the endotoxemia 
animals. So, both the endotoxin-induced decline and increase of leukocyte 
numbers is not influenced by the exogenously administered proteinase 
inhibitors. 
Factors of the Clotting, Fibrinolysis and Complement Systems. Figure 4 
summarizes the patterns of the chosen parameters as obtained under var­
ious inhibitor applications. During therapy with the elastase-cathepsin G-
inhibitor BBI, the endotoxin-induced decrease of the measured plasma fac­
tor levels (fig. 3B) was reduced after 14 h (p < 0.05) as shown in figure 4B. 
The corresponding mean values and their standard deviations are compiled 
in table III. Remarkably, the positive influence of the inhibitor medication 
was independent of the applied dose (3-8 mg/kg body weight) suggesting 
that even the lowest inhibitor dosage used (3 mg) was capable of preventing 
Table I I I . Changes in the plasma levels o f various plasma factors during the acute phase o f experimental 
endotoxemia in dogs and under inhibi tor medication 
Parameter Test Control Endotoxin BBI Aprot in in 
t ime group group group group 
h (n = 6) (n = 6) (n = 4) (n = 6) 
Factor X I I I 0 100 100 100 100 
2 94.0 ± 4.0 88.0 ± 3.0 101.5 ± 1.5 95.2 ± 5.2 
6 94.2 ± 4.7 63.2 ± 4.2 98.3 ± 1.8 85.2 ± 4.4 
10 99.2 ± 1.3 51.0 + 4.0 96.5 ± 2.1 76.7 ± 7.2 
14 94.5 + 3.0 41.2 ± 4.3 98.3 ± 1.8 71.7 ± 7.9 
Prothrombin 0 100 100 100 100 
2 90.0 ± 3.0 78.0 ± 8.5 101.8 ± 2.7 88.2 ± 7.1 
6 93.7 ± 2.7 48.0 ± 11.5 88.5 ± 4.7 91.0 ± 1.8 
10 85.0 ± 3.5 40.0 ± 9.0 81.5 ± 6.2 82.3 ± 6.4 
14 82.7 ± 5.7 40.0 ± 9.0 83.0 ± 6.6 81.2 ± 4.2 
Ant i th rombin I I I 0 100 100 100 100 
2 90.0 ± 3.7 87.0 ± 7.0 97.8 ± 5.8 86.8 ± 8.6 
6 93.8 ± 2.4 67.0 ± 8.0 85.3 ± 7.9 89.7 ± 3.9 
10 83.0 ± 2.7 65.0 ± 8.0 87.0 ± 5.8 74.5 ± 11.0 
14 82.0 ± 3.2 67.0 ± 9.0 84.0 ± 8.5 77.2 ± 6.5 
Plasminogen 0 100 100 100 n.d. 
2 109.0 ± 2.8 78.0 ± 13.0 109.3 ± 3.8 
6 102.0 ± 3.0 64.0 ± 11.0 87.3 ± 6.9 
10 96.0 ± 3.7 57.0 ± 9.3 86.0 ± 11.3 
14 96.0 ± 4.3 50.0 ± 7.0 87.5 ± 6.5 
Antiplasmin 0 100 100 100 n.d. 
2 93.5 ± 3.7 80.7 ± 7.5 97.0 ± 6.4 
6 92.5 ± 2.7 55.5 ± 8.3 78.3 ± 9.9 
10 86.2 ± 5.5 52.5 ± 5.7 85.3 ± 6.7 
14 87.5 ± 4.0 52.5 ± 7.5 89.0 ± 8.4 
Complement C3 0 100 100 100 100 
2 90.7 ± 4.3 62.5 ± 10.0 89.3 ± 10.1 90.6 ± 7.9 
6 88.3 ± 5.0 47.0 ± 8.8 74.3 ± 4.9 76.6 ± 4.4 
10 80.7 ± 6.0 41.3 ± 5.7 75.3 ± 9.8 75.2 ± 6.1 
14 88.0 ± 4.0 33.7 ± 3.7 78.0 ± 9.3 74.4 ± 8.0 
The data o f each group at different test times are indicated as percentages o f the individual starting values 
(mean values ± SEM). The endotoxin infusion (2 mg/kg body weight) was performed for the first 2 h, the 
inhibi tor infusion (per kg body weight 3 or 8 mg BBI and 40,000 or 80,000 kallikrein inhibi tor units o f 
aprotinin, respectively) for the whole observation period (14 h). 
The statistical significance was evaluated by the three-way analysis o f variance (p < 0.05/0.001 for the 
differences between the control and the endotoxin group) and by Student's t test (p < 0.05/0.01 for the 
differences between the endotoxin group and each inhibitor-medicated group). For further details, see text, 
n.d. = Not done because the aprotinin present i n the plasma acts as a strong plasmin inhibitor. 
Proteinase Inhibitors in Experimental Endotoxemia 163 
the endotoxin-induced degradation of the plasma proteins. In addition, the 
broad spectrum proteinase inhibitor aprotinin also significantly prevented 
the endotoxin-induced decline of the coagulation and complement proteins 
(fig. 4A). In this case the fibrinolysis factors (plasminogen and antiplasmin) 
could not be assayed with the chromogenic substrate because aprotinin 
present in the plasma samples acts as a strong plasmin inhibitor. 
Discussion 
In recent years, numerous reports have been published dealing with 
endotoxin-induced changes of hematological and biochemical parameters 
in various mammalian species. Due to different sensitivities of the diverse 
species to endotoxin [14, 21] as well as to different experimental approaches 
[1, 32] individual results can be compared only with strong reservations. 
Therefore, we took advantage of an experimental procedure enabling us to 
study some of the most interesting factors simultaneously with the intention 
of establishing a statistically verifiable model of endotoxemia. 
Indeed, the statistical evaluation displayed the differences in the levels 
of the various parameters as being significant (p < 0.05) for the control and 
endotoxemia group, the test times and the time course. This clearly shows 
the validity of our experimental model as a convenient model of endotox-
emia. Obviously, the substantial alterations in blood cell counts and in 
plasma protein levels are characteristic for endotoxin-induced DIC, espe-
cially the decrease in blood platelets and the activation and consumption of 
clotting and fibrinolysis factors [1, 3, 16, 28, 30]. Moreover, a significant 
loss of factor C3 of the complement system could be observed in the early 
hours of the experimental period. Although the relationship between the 
complement and the coagulation-fibrinolysis systems is only partly defined 
as yet [6, 16, 31], involvement of the complement systems seems to be a 
major requirement for the full expression of progressive DIC in endotox-
emia. Activation of the complement system via the alternative pathway, 
that means via C3, should be due not only to direct endotoxin action [17] 
but also to proteolysis by plasmin liberated during endotoxemia [3, 13, 14, 
42]. In addition, plasmin has been shown to activate complement factor C I 
[36] thus causing complement consumption through the classical pathway. 
The given assumptions are in agreement with recent observations of Aasen 
et al. [4], indicating complement activation via both pathways in the course 
of canine endotoxin shock. 
Jochum/Witte/Schiessler/Selbmann/Ruckdeschl/Fritz 164 
It should be emphasized, however, that besides activation of comple-
ment in connection with DIC, also a direct activation of factor C3 by gran-
ulocytic elastase may occur [23]. In fact, Aasen and Ohlsson [2] recently 
demonstrated release of granulocytic elastase in canine endotoxin shock, 
regularly accompanied by a marked decrease in the concentration of factor 
C3. 
Although D I C certainly arises in the course of septicemia and acute 
myeloic leukemia [8, 10], there is also strong evidence of a direct proteolysis 
of coagulation factors by granulocytic proteinases. For example, Egbring et 
al. [8] and Egbring and Havemann [10] were able to demonstrate that sub-
unit A (the active transglutaminase) and subunit S (the carrier protein) of 
F XIII were consumed to a comparable degree throughout the above-men-
tioned diseases. The reduction of both subunits, however, is not consistent 
with the usual consumption of F X I I I during blood clotting, since subunit A 
and F X I I I activity disappear completely after coagulation of plasma, 
whereas subunit S remains unchanged. As the elastase-like granulocytic pro-
teinase (ELP) caused a similar reduction of the activity of both F XIII sub-
units in plasma, the authors suggested that unspecific proteolysis by E L P is 
involved to an appreciable degree in patients with septicemia and acute 
leukemia. 
The results of our experimental approach are an indirect but clear indi-
cation that besides DIC unspecific proteolysis has to be considered as an 
important factor responsible for the severe consumption of C3, F X I I I and 
other plasma proteins as well. This conclusion is based on the observation 
that upon medication with BBI, a relative specific inhibitor of granulocytic 
elastase and cathepsin G, the decrease of the plasma protein levels was 
prevented highly significantly, though not totally (fig. 4B). In this respect the 
F XIII level is of special interest. Upon BBI infusion the endotoxin-induced 
fall of F XIII activity was completely prevented (fig. 4B), whereas upon 
application with aprotinin, which is supposed to inhibit preferable plasmin 
and plasma kallikrein, a considerable reduction of the F XIII clotting activ-
ity was maintained (fig. 4A). This indicates that F X I I I inactivation is rather 
due to unspecific proteolysis than to DIC, thus confirming results of more 
recent studies dealing with gram-negative sepsis in dogs [38]. 
The residual consumption of the other plasma factors during BBI med-
ication (fig. 4B) should reflect, at least to some extent, their DIC-induced 
elimination. However, quantitation of the degree of consumption due to 
either unspecific proteolysis or D I C is not yet feasible. On one hand, our 
knowledge on the interrelations between both mechanisms as well as on the 
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inhibition spectrum of both inhibitors is still incomplete. On the other 
hand, aprotinin was applied in an unusually high dosage (corresponding to 
2.8 and 5.6 Χ 106 kallikrein inhibitor units within 14 h in a 70-kg patient) 
so that at least partial inhibition of elastase and cathepsin G by this drug 
cannot be excluded; a specific affinity of aprotinin to both proteinases has 
been recently reported [12]. That means, in the aprotinin-treated animals 
the degree of reduction of the plasma factors (fig. 4A) probably does not 
only reflect the prevention of DIC-induced consumption, but also the effect 
of other properties of this drug [12] not yet quantifiable in our experimental 
model. 
The present study indicates clearly that during inflammatory processes, 
such as septicemia or endotoxemia, the potential of the plasma proteinase 
inhibitors may be considerably overstressed, thus leading to severe degra­
dation of the blood system proteins. Obviously, the liberated granulocytic 
proteinases can degrade individual factors in a pathophysiological^ rele­
vant extent already in the presence of an excess of the plasmatic antipro-
teinases. Results of in vitro investigations from Egbring et al. [8] confirm 
this view. The authors showed that elastase-like and chymotrypsin-like pro­
teinases are able to degrade several coagulation factors in plasma although 
the antiproteinase capacity of arantitrypsin, cb-macroglobulin and a r anti-
chymotrypsin has not been exhausted. As shown for the first time in our 
endotoxemia model, application of a suitable inhibitor of leukocytic pro­
teinase (BBI) can significantly prevent unspecific degradation of plasma 
proteins, thus maintaining the physiological balance of the natural defence 
mechanisms. However, it is just as important to minimize simultaneously 
DIG induced by system-specific proteinases throughout the inflammatory 
diseases. For the latter purpose aprotinin (Trasylol®), already used in med­
ical therapy, and/or the thrombin-specific inhibitor hirudin are potential 
candidates, whereas BBI or inhibitors with similar properties might be 
applied in future to prevent unspecific proteolysis. 
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